Clavis, Clovis Shares Plunge on CO-101 Pancreatic Cancer Miss
By Cormac Sheridan
Wednesday, November 14, 2012
Shares in Clavis Pharma ASA (OSLO:CLAVIS) plummeted by more than 87 percent Monday following the failure of CO-101 (CP-4126) to demonstrate any impact on survival in a pivotal Phase II trial in metastatic pancreatic cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.